Andrew Spaventa Sells 695 Shares of Singular Genomics Systems, Inc. (NASDAQ:OMIC) Stock

Singular Genomics Systems, Inc. (NASDAQ:OMIC) CEO Andrew Spaventa sold 695 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $22.55, for a total value of $15,672.25. Following the completion of the transaction, the chief executive officer now directly owns 1,537 shares of the company’s stock, valued at $34,659.35. The trade was a 31.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Andrew Spaventa also recently made the following trade(s):

• On Sunday, September 15th, Andrew Spaventa sold 175 shares of Singular Genomics Systems stock. The shares were sold at an average price of $12.38, for a total value of $2,166.50.

Singular Genomics Systems Price Performance

Shares of OMIC opened at $22.75 on Friday. The company has a quick ratio of 8.04, a current ratio of 7.37 and a debt-to-equity ratio of 0.04. Singular Genomics Systems, Inc. has a 1-year low of $5.34 and a 1-year high of $23.41. The firm’s 50 day simple moving average is $15.32 and its 200 day simple moving average is $11.33.

Singular Genomics Systems (NASDAQ:OMIC) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($6.72) EPS for the quarter, beating the consensus estimate of ($8.05) by $1.33. The firm had revenue of $0.41 million for the quarter, compared to analyst estimates of $0.74 million. Singular Genomics Systems had a negative return on equity of 57.87% and a negative net margin of 3,237.89%.

About Singular Genomics Systems

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.